Insmed Incorporated cash flow to debt ratio of -121.72% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Insmed Incorporated's free cash flow has decreased 37.09% from $-705.80M last year to $-967.58M, signaling decreasing performance

Insmed Incorporated's debt to equity ratio is 1.06, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Insmed Incorporated's debt has decreased relative to shareholder equity from 4.60 last year to 1.06 today, signaling strengthened financials

Insmed Incorporated has negative EBITDA, making leverage ratio unreliable

Insmed Incorporated's interest coverage ratio is -13.72, which means that the company struggles to meet interest obligations, signaling financial risk.

Insmed Incorporated's profit margin has increased (-42.51%) in the last year from -251.24% to -144.44%, signaling increasing performance

Insmed Incorporated's short-term assets of $1.79G exceed its short-term liabilities of $468.87M

Insmed Incorporated's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Insmed Incorporated's return on equity of -130.11%, is lower than 15.00%, indicating bad performance

Insmed Incorporated's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Insmed Incorporated had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Insmed Incorporated has negative free cash flow, indicating the company is burning cash rather than generating it

Insmed Incorporated has negative free cash flow, indicating cash burn

Insmed Incorporated's yearly earnings has decreased 39.73% since last year from $-913.77M to $-1.28G, signaling decreasing performance

Insmed Incorporated's yearly revenue has increased 66.73% since last year from $363.71M to $606.42M, signaling increasing performance

ROIC -65.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Insmed Incorporated's 3-year revenue CAGR of 35.20% is positive, indicating growing revenue over the past 3 years

Insmed Incorporated had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Insmed Incorporated had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Insmed Incorporated has insufficient data to evaluate this check.

Insmed Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Insmed Incorporated is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Insmed Incorporated has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Insmed Incorporated is overvalued relative to its fair value price of -109.35 based on Earnings Fair Value model

Insmed Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Insmed Incorporated has a price-to-book ratio of 33.66x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Insmed Incorporated has a price-to-sales ratio of 28.95x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue